ISSN: 2633-4828 Vol. 4 No.2, September, 2022

International Journal of Applied Engineering & Technology

A Survey On Deep Learning Methods For Prostate Cancer Detection And Classification Using MRI Images

Goddumarri Vijay Kumar[1] , Mohammed Ismail B[2] , Thota Bhaskara Reddy[3]
[1]Research Scholar, Dept. of Computer Science and Technology, Sri Krishnadevaraya University, Anantapur (A.P.) – INDIA.
[2]Professor, Department of Artificial Intelligence and Machine Learning, P.A. College of Engineering, Mangalore, Affiliated to Visvesvaraya Technological University, Belgavi, India.
[3]Professor, Dept. of Computer Science and Technology, Sri Krishnadevaraya University, Anantapur (A.P.) – INDIA.

Abstract
The prostate is a small walnut-sized gland located below the bladder and surrounding the urethra in males. It plays a crucial role in producing seminal fluid, which nourishes and transports sperm. Abnormal growth of prostate cells can lead to the development of prostate cancer, one of the most common malignancies among men worldwide.Prostate cancer (PCa) remains one of the most prevalent cancers among men and is a leading cause of cancer-related mortality worldwide. Accurate detection and classification of prostate cancer are vital for early treatment and reducing mortality rates. Recent advances in deep learning, particularly convolutional neural networks (CNNs), have revolutionized medical imaging by enabling automated feature extraction and lesion characterization. Multi-parametric Magnetic Resonance Imaging (mp-MRI) provides a rich source of anatomical and functional data, enabling superior prostate cancer diagnosis compared to conventional imaging modalities. This survey explores existing deep learning-based methods for prostate cancer detection, segmentation, and classification using MRI images. The paper discusses conventional methods, major deep learning architectures, hybrid optimization approaches, challenges, datasets, and future directions for research. This work aims to provide a detailed overview of the field and to guide future researchers toward more robust and clinically applicable diagnostic models.

***Keywords** Deep Learning; Prostate Cancer; MRI; Classification; Convolutional Neural Networks; Transfer Learning; Image Segmentation; Optimization Algorithms.*

I. Introduction

The prostate gland is a vital component of the male reproductive system, located below the bladder and encircling the urethra. Its primary function is to secrete seminal fluid that supports and protects sperm during ejaculation. Due to its anatomical position and physiological role, the prostate is prone to disorders, including inflammation, enlargement, and malignancy — the most serious being prostate cancer. Prostate cancer (PCa) is the second most commonly diagnosed cancer among men and a leading cause of cancer-related death. According to global statistics, one in nine men will be diagnosed with prostate cancer during their lifetime. Approximately 90% of these cases are categorized as low-risk, with a Gleason Score (GS) ≤ 6, and require only active surveillance rather than aggressive treatment. However, clinically significant (CS) prostate cancer, defined by GS ≥ 7, often leads to metastasis and high fatality rates if not diagnosed early. Therefore, distinguishing CS PCa from non-CS PCa is critical to avoid overtreatment and to focus on cases requiring medical intervention.

Being the prostate gland, a small walnut-sized organ located below the bladder and surrounding the urethra,detecting abnormalities in such a small region demands high-resolution imaging and precise interpretation. Conventional diagnostic approaches—such as Prostate-Specific Antigen (PSA) tests and Trans-Rectal Ultrasound (TRUS)—suffer from limitations such as invasiveness, low specificity, and false positives.

Multi-parameter Magnetic Resonance Imaging (mp-MRI) has emerged as a reliable and non-invasive modality for prostate imaging. It combines multiple sequences—T2-weighted (T2w), Diffusion-Weighted Imaging (DWI) and Apparent Diffusion Coefficient (ADC)imaging—providing complementary information about tissue anatomy, structure, and function. Table 1 gives the overview of multi-parameter MRI modalities, imaging principles and their roles in tissue differentiation. Despite its diagnostic superiority, interpreting mp-MRI data requires significant expertise and is subject to inter-observer variability. This has spurred the adoption of Deep Learning (DL) techniques to automate and enhance detection accuracy.

Table 1: Overview of mp-MRI Modalities, sequences and their roles in tissue differentiation.

MRI Sequence	Imaging Principle	Diagnostic Role in Prostate Cancer	Key Advantages	Limitations
T2-Weighted (T2w)	Measures differences in transverse relaxation time (T2) of water protons in tissues.	Provides detailed **anatomical structure** of the prostate, zonal differentiation between peripheral and transition zones, and detection of structural abnormalities.	Excellent soft tissue contrast; helps visualize capsule and tumor boundaries.	Limited functional information; may not differentiate benign from malignant lesions alone.
DWI **Diffusion-Weighted Imaging**	Based on the **Brownian motion** of water molecules within tissues.	Detects **restricted diffusion** in cancerous tissue due to higher cell density. Often used to locate tumor foci.	Sensitive to cellular density; useful for identifying CS lesions.	Susceptible to artifacts and distortion; needs high b-values for accuracy.
ADC Map **Apparent Diffusion Coefficient**	Quantitative map derived from DWI signal decay at multiple b-values.	Provides a **quantitative measure** of water diffusivity; low ADC values correspond to high tumor aggressiveness.	Enables objective differentiation of cancer grades; valuable for Gleason scoring.	ADC values may overlap between benign and malignant tissues; sensitive to noise.

II. Related Work

Computer-Aided Diagnosis (CAD) systems for prostate cancer aim to support radiologists in lesion localization and classification. Traditionally, CAD systems consist of three steps: image registration to align different modalities, prostate segmentation to isolate the gland, and lesion detection or classification to differentiate CS from non-CS PCa. Early CAD models relied on handcrafted features such as texture, intensity, and statistical measures extracted from MRI modalities. However, these features were often insufficient for capturing complex spatial and contextual information.

The advent of Deep Learning has transformed CAD pipelines into end-to-end automated systems. CNNs, U-Nets, and hybrid deep architectures can learn hierarchical features directly from raw image data, outperforming traditional methods. Several studies have applied deep learning to tasks such as prostate segmentation, lesion classification, and Gleason grading. Transfer learning approaches using pre-trained models (e.g., ResNet, VGG, EfficientNet) have also been employed to mitigate limited data availability.

III. Literature Review

At the core of most deep learning–based prostate cancer detection systems lies a systematic workflow involving multiple stages. As shown in **Figure 1**, the process typically begins with input MRI images followed by pre-processing, segmentation, feature extraction, and classification. Each stage contributes to progressively enhancing the data representation and improving the accuracy of clinically significant prostate cancer identification.



Figure 1: Workflow of Deep Learning-based Prostate Cancer Detection

A. End-to-End Deep Neural Networks - Wang et al. (2018) developed an end-to-end deep neural network for detecting CS PCa in mp-MRI. Their model incorporated prostate segmentation and lesion classification in a unified framework, achieving high sensitivity and specificity.

B. Radiomics-Based Models - Cameron et al. (2016) introduced the MAPS framework, which integrates quantitative radiomic features extracted from mp-MRI. Although effective, radiomics models rely heavily on handcrafted features, limiting scalability and requiring expert feature selection.

C. Hybrid Optimization-Based Neural Networks - Recent research has explored optimization algorithms like Bird Swarm Algorithm (BSA) and Squirrel Search Algorithm (SSA) to fine-tune neural network parameters. These methods improve convergence and reduce overfitting when applied to small MRI datasets.

D. 3D CNNs and Transfer Learning - Zhong et al. (2018) and Aldoj et al. (2019) demonstrated that 3D CNNs using multiple MRI channels (T2w, ADC, DWI) improve contextual learning and diagnostic accuracy. Transfer learning from pre-trained networks helps overcome limited prostate MRI data.

E. Gene Expression and Deep Learning Integration - Tirumala and Narayanan (2018) combined gene expression analysis with artificial neural networks to predict prostate cancer progression. Though promising, these approaches require validation across multiple datasets for broader applicability.

IV. Evaluation Metrics and Statistical Features

In prostate cancer detection and classification using MRI, performance evaluation relies on quantitative metrics that assess how accurately a deep learning model can differentiate between malignant and benign regions. Before these high-level metrics are computed, a few basic statistical features are extracted from the model outputs and ground truth data to form the foundation for evaluation.

A. Essential Statistical Features

Commonly used statistical features in MRI-based cancer analysis include:

- **Mean (μ):** Represents the average intensity value of the prostate region in an image.

  $$\mu = \frac{1}{N}\sum_{i=1}^{N} x_i$$

  where x_i denotes the pixel intensity and N is the total number of pixels.
- **Standard Deviation (σ):** Measures the dispersion or contrast of pixel intensities within the prostate region.

  $$\sigma = \sqrt{\frac{1}{N-1}\sum_{i=1}^{N}(x_i - \mu)^2}$$

- **Kurtosis:** Describe the asymmetry and peakedness of the pixel intensity distribution, helping to distinguish tissue characteristics between healthy and cancerous areas.

These statistical descriptors are often combined with learned deep features to enhance the discriminative power of classification models.

B. Evaluation Metrics

After feature extraction and classification, model performance is quantitatively assessed using **Accuracy**, **Sensitivity**, and **Specificity** — three fundamental metrics that determine the reliability and clinical usefulness of the model.

Let:

- **TP (True Positives):** correctly identified cancerous cases
- **TN (True Negatives):** correctly identified non-cancerous cases
- **FP (False Positives):** benign cases incorrectly classified as cancer
- **FN (False Negatives):** cancerous cases missed by the model

1. Accuracy

Accuracy measures the overall correctness of the model in classifying both cancerous and non-cancerous samples.

$$\text{accuracy} = \frac{TP + TN}{TP + TN + FP + FN}$$

A high accuracy indicates strong overall classification performance, though it may be biased in cases of class imbalance.

2. Sensitivity
Sensitivity measures the model's ability to correctly identify patients with prostate cancer.

$$\text{sensitivity} = \frac{\text{TP}}{\text{TP} + \text{FN}}$$

A high sensitivity ensures that clinically significant prostate cancers are not missed, making it crucial for medical diagnosis where false negatives can be life-threatening.

3. Specificity
Specificity measures how effectively the model identifies healthy or benign cases.

$$\text{specificity} = \frac{\text{TN}}{\text{TN} + \text{FP}}$$

High specificity indicates fewer false alarms, reducing unnecessary biopsies and clinical interventions.

C. Importance in Clinical Context
In clinical applications, Sensitivity is prioritized for ensuring that all cancer-positive cases are detected, while Specificity prevents misclassification of benign regions that could lead to overtreatment. Therefore, an ideal diagnostic system maintains a balanced trade-off between sensitivity and specificity while achieving high overall accuracy.

Recent studies have demonstrated that deep learning models can achieve accuracy levels exceeding 90%, with sensitivity and specificity values often surpassing 88% and 92%, respectively. These promising results indicate that deep learning frameworks are capable of accurately identifying clinically significant prostate cancer from MRI images. Such performance levels suggest a strong potential for automated prostate cancer detection and classification, paving the way for their integration into clinical diagnostic workflows in the near future.

V. Challenges and Limitations
Despite impressive progress, several challenges hinder clinical adoption of deep learning models for prostate cancer detection:

Table 2: Summarizes major challenges and future trends in Deep Learning for MRI analysis

Challenge	Description	Impact	Future Direction
3D Model Complexity	Extending CNNs to 3D improves spatial understanding but requires high computational power and large memory.	Increases training time and limits deployment in low-resource environments.	Develop lightweight 3D architectures and efficient model optimization techniques.
Data Scarcity	Limited availability of annotated prostate MRI datasets restricts model generalization.	Causes reduced robustness and reliability on unseen data.	Encourage data sharing, use augmentation, and leverage transfer learning.

Overfitting	Augmented datasets often lack sufficient variability to simulate real-world conditions.	Models perform well on training data but fail during validation or testing.	Apply advanced augmentation, regularization, and cross-validation strategies.
Interpretability	Deep learning models act as "black boxes," offering limited insight into decisions.	Reduces clinician confidence and slows clinical adoption.	Present outputs with clear visual or numerical indicators understandable by clinicians.
Cross-Institution Variability	MRI scanners and acquisition protocols differ across hospitals and manufacturers.	Causes inconsistency and performance drop across datasets.	Use normalization and domain adaptation to improve generalization.
Clinical Integration	Lack of standardized pipelines for integrating AI models into hospital systems.	Delays real-time usage and decision support in clinical settings.	Develop standardized, compatible, and workflow-friendly AI deployment systems.

VI. Conclusion

Deep learning has emerged as a powerful tool in prostate cancer detection and classification using MRI images, offering automated, consistent, and highly accurate diagnostic capabilities. With the evolution from traditional handcrafted radiomics features to advanced architectures such as 3D CNNs, U-Nets, and hybrid optimization-driven networks, remarkable improvements have been achieved in both segmentation and classification accuracy. Statistical and performance metrics such as accuracy, sensitivity, and specificity have consistently demonstrated values above 90%, validating the reliability of deep learning–based systems in identifying clinically significant prostate cancer.

Despite this progress, challenges persist—particularly in managing limited and imbalanced data, computational demands, and variations in MRI acquisition protocols. Addressing these issues through larger datasets, optimized lightweight architectures, and standardized clinical integration will be essential to ensure widespread applicability.

Overall, deep learning continues to provide strong evidence that automated prostate cancer detection and classification are achievable with clinical-grade reliability. As these systems mature, their seamless integration into radiology workflows has the potential to support early diagnosis, reduce human subjectivity, and enable personalized and precise prostate cancer care in real-world healthcare environments.

References

[1] Wang, Z., Liu, C., Cheng, D., Wang, L., Yang, X., & Cheng, K.-T. , "Automated Detection of Clinically Significant Prostate Cancer in mp-MRI Images Based on an End-to-End Deep Neural Network," IEEE Transactions on Medical Imaging, vol.37, no.5, pp.1127–1139, 2018.
[2] Cameron, A., Khalvati, F., Haider, M. A., & Wong, A., " MAPS: A Quantitative Radiomics Approach for Prostate Cancer Detection," IEEE Transactions on Biomedical Engineering, vol.63, no.6, pp.1145–1156, 2016.

[3] Shakeel, P. M., & Manogaran, G.," Prostate cancer classification from prostate biomedical data using ant rough set algorithm with radial trained extreme learning neural network," Health and Technology, 2018.
[4] Tirumala, S. S., & Narayanan, A. "Classification and diagnostic prediction of prostate cancer using gene expression and artificial neural networks," Neural Computing and Applications, 2018.
[5] Zhong, X., Cao, R., Shakeri, S., Scalzo, F., Lee, Y., Enzmann, D. R., Sung, K., " Deep transfer learning-based prostate cancer classification using 3 Tesla multi-parametric MRI," Abdominal Radiology, 2018.
[6] Aldoj, N., Lukas, S., Dewey, M., & Penzkofer, T., " Semi-automatic classification of prostate cancer on multi-parametric MR imaging using a multi-channel 3D convolutional neural network," European Radiology, 2019.
[7] Kumar, R., Bhanti, P., Marwal, A., & Gaur, R. K., "Gene Expression-Based Supervised Classification Models for Discriminating Early- and Late-Stage Prostate Cancer," Proceedings of the National Academy of Sciences, India Section B: Biological Sciences, 2019.
[8] Shahbeig, S., Rahideh, A., Helfroush, M. S., & Kazemi, K. ,"Gene expression feature selection for prostate cancer diagnosis using a two-phase heuristic–deterministic search strategy," IET Systems Biology, vol.12, no.4, pp.162–169, 2018.
[9] G. Litjens, O. Debats, J. Barentsz, N. Karssemeijer, and H. Huisman, "Computer-aided detection of prostate cancer in mri," IEEE transactions on medical imaging, vol. 33, no. 5, pp. 1083–1092, 2014.
[10] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015," CA: a cancer journal for clinicians, vol. 65, no. 1, pp. 5–29, 2015.
[11]D. Fehr, H. Veeraraghavan, A. Wibmer, T. Gondo, K. Matsumoto, H. A. Vargas, E. Sala, H. Hricak, and J. O. Deasy, "Automatic classification of prostate cancer gleason scores from multiparametric magnetic resonance images," Proceedings of the National Academy of Sciences, vol. 112, no. 46, pp. E6265–E6273, 2015.
[12] G. Lemaitre, "Computer-aided diagnosis for prostate cancer using multiparametric magnetic resonance imaging," Ph.D. dissertation, Universite de Bourgogne; Universitat de Girona, 2016.
[13] G. Litjens, J. Barentsz, N. Karssemeijer, and H. Huisman, "Automated computer-aided detection of prostate cancer in mr images: from a whole-organ to a zone-based approach," in SPIE Medical Imaging. International Society for Optics and Photonics, pp. 83 150G– 83 150G, 2012.
[14] Y. Artan, M. A. Haider, D. L. Langer, T. H. van der Kwast, A. J. Evans, Y. Yang, M. N. Wernick, J. Trachtenberg, and I. S. Yetik, "Prostate cancer localization with multispectral mri using cost-sensitive support vector machines and conditional random fields," IEEE Transactions on Image Processing, vol. 19, no. 9, pp. 2444–2455, 2010.
[15] V. Giannini, S. Mazzetti, A. Vignati, F. Russo, E. Bollito, F. Porpiglia, M. Stasi, and D. Regge, "A fully automatic computer aided diagnosis system for peripheral zone prostate cancer detection using multi-parametric magnetic resonance imaging," Computerized Medical Imaging and Graphics, vol. 46, pp. 219–226, 2015.
[16] S. Ozer, M. A. Haider, D. L. Langer, T. H. van der Kwast, A. J. Evans, M. N. Wernick, J. Trachtenberg, and I. S. Yetik, "Prostate cancer localization with multispectral mri based on relevance vector machines," in Biomedical Imaging: From Nano to Macro, 2009. ISBI'09. IEEE International Symposium on. IEEE, pp. 73–76, 2009.
[17] P. Puech, N. Betrouni, N. Makni, A.-S. Dewalle, A. Villers, and L. Lemaitre, "Computer-assisted diagnosis of prostate cancer using dcemridata: design, implementation and preliminary

results," International journal of computer assisted radiology and surgery, vol. 4, no. 1, pp. 1–10, 2009.
[18] P. C. Vos, T. Hambrock, C. A. Hulsbergen-van de Kaa, J. J. F¨utterer, J. O. Barentsz, and H. J. Huisman, "Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced mri," Medical Physics, vol. 35, no. 3, pp. 888–899, 2008.
[19] Arumainayagam et al. Multiparametric MR Imaging for Detection of Clinically Significant Prostate Cancer: A Validation Cohort Study with Transperineal Template Prostate Mapping as the Reference Standard. Radiology, vol.268, no.3, pp:761–769, 2013.
[20] Prostate MRI Dataset, " https://prostatemrimagedatabase.com/", Accessed on January 2020.
[21] Meng, X.-B., Gao, X. Z., Lu, L., Liu, Y., & Zhang, H. , "A new bio-inspired optimisation algorithm: Bird Swarm Algorithm," Journal of Experimental & Theoretical Artificial Intelligence, vol.28, no.4, pp.673–687, 2015.
[22] Jain, M., Singh, V., & Rani, A., "A novel nature-inspired algorithm for optimization: Squirrel search algorithm," Swarm and Evolutionary Computation, 2018.